Marvin White - Aptevo Therapeutics CEO President
| APVO Stock | USD 4.83 5.18 51.75% |
CEO
Marvin White is CEO President of Aptevo Therapeutics
| Age | 62 |
| Address | 2401 4th Avenue, Seattle, WA, United States, 98121 |
| Phone | 206 838 0500 |
| Web | https://www.aptevotherapeutics.com |
Marvin White Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marvin White against Aptevo Therapeutics stock is an integral part of due diligence when investing in Aptevo Therapeutics. Marvin White insider activity provides valuable insight into whether Aptevo Therapeutics is net buyers or sellers over its current business cycle. Note, Aptevo Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Aptevo Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marvin White over three months ago Acquisition by Marvin White of 9584 shares of Aptevo Therapeutics at 0.001 subject to Rule 16b-3 | ||
Marvin White over six months ago Disposition of 9584 shares by Marvin White of Aptevo Therapeutics subject to Rule 16b-3 | ||
Marvin White over six months ago Disposition of 12917 shares by Marvin White of Aptevo Therapeutics subject to Rule 16b-3 | ||
Marvin White over a year ago Exercise or conversion by Marvin White of 7200 shares of Emergent Biosolutions subject to Rule 16b-3 |
Aptevo Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.7275) % which means that it has lost $0.7275 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.5096) %, meaning that it created substantial loss on money invested by shareholders. Aptevo Therapeutics' management efficiency ratios could be used to measure how well Aptevo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Tangible Assets is likely to drop to -0.74. In addition to that, Return On Capital Employed is likely to drop to -1.72. At this time, Aptevo Therapeutics' Net Tangible Assets are very stable compared to the past year. As of the 13th of December 2024, Other Current Assets is likely to grow to about 3 M, while Total Assets are likely to drop about 23.6 M.Similar Executives
| Found 9 records | CEO Age | ||
| Norbert Bischofberger | Kronos Bio | 68 | |
| Heidi MS | Invivyd | N/A | |
| HyungHeon Kim | Neurobo Pharmaceuticals | 49 | |
| Carole MD | Larimar Therapeutics | 65 | |
| Shaun Bagai | RenovoRx | 47 | |
| Mohamed Hashad | Longeveron LLC | 62 | |
| William MD | Passage Bio | 51 | |
| Mohamed MBA | Longeveron LLC | 62 | |
| Gareth Sheridan | Nutriband | 34 | |
Management Performance
| Return On Equity | -2.51 | ||||
| Return On Asset | -0.73 |
Aptevo Therapeutics Leadership Team
Elected by the shareholders, the Aptevo Therapeutics' board of directors comprises two types of representatives: Aptevo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptevo. The board's role is to monitor Aptevo Therapeutics' management team and ensure that shareholders' interests are well served. Aptevo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptevo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marvin White, CEO President | ||
| Dirk MD, Chief Officer | ||
| Jane Gross, Chief Officer | ||
| Daphne Taylor, Senior CFO | ||
| Jeffrey CA, Executive COO | ||
| LLM JD, General VP | ||
| Daphne CPA, Senior CFO |
Aptevo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptevo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.51 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 2.09 M | ||||
| Shares Outstanding | 500.33 K | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 11.36 % | ||||
| Number Of Shares Shorted | 1.41 M | ||||
| Price To Earning | 2.48 X | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 1.61 X |
Pair Trading with Aptevo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Aptevo Stock
| 0.54 | IMAB | I Mab | PairCorr |
| 0.43 | GNFT | Genfit | PairCorr |
| 0.38 | FLGC | Flora Growth Corp Buyout Trend | PairCorr |
| 0.38 | LLY | Eli Lilly | PairCorr |
| 0.36 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (415.99) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (2.51) |
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.